Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas

JC Dujardin, D González-Pacanowska, SL Croft, OF Olesen, GF Späth

    Research output: Contribution to journalA1: Web of Science-articlepeer-review


    The protozoan diseases leishmaniasis, human African trypanosomiasis and Chagas disease are responsible for substantial global morbidity, mortality and economic adversity in tropical and subtropical regions. In most countries, existing strategies for control and treatment are either failing or under serious threat. Environmental changes, drug resistance and immunosuppression contribute to the emergence and spread of these diseases. In the absence of safe and efficient vaccines, chemotherapy, together with vector control, remains the most important measures to control trypanosomatid diseases. Here, we review current limitations of anti-trypanosomatid chemotherapy and describe new efforts to safeguard existing treatments and to identify novel drug leads through the three multinational and interdisciplinary European Union Framework Programmes for Research and Technological Development (FP7) funded consortia KALADRUG-R, TRYPOBASE, and LEISHDRUG
    Original languageEnglish
    JournalTrends In Parasitology
    Issue number8
    Pages (from-to)395-403
    Number of pages9
    Publication statusPublished - 2010


    • B780-tropical-medicine
    • Protozoal diseases
    • Visceral
    • Leishmaniasis
    • Kala azar
    • Leishmania donovani
    • Leishmania infantum
    • Trypanosomatids
    • Impact
    • Distribution
    • Treatment
    • Drugs
    • International collaboration
    • Drug development
    • Tools
    • Monitoring
    • Drug resistance
    • Review of the literature


    Dive into the research topics of 'Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas'. Together they form a unique fingerprint.

    Cite this